Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial.

@article{Dudek2012FouryearCF,
  title={Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial.},
  author={Dariusz Dudek and Yoshinobu Onuma and John A Ormiston and Leif Thuesen and Karine Miquel-H{\'e}bert and Patrick Washington Serruys},
  journal={EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology},
  year={2012},
  volume={7 9},
  pages={1060-1}
}
AIM The first-in-man ABSORB Cohort A trial demonstrated the bioresorption of the ABSORB BVS (Abbott Vascular, Santa Clara, CA, USA) at two years. This report describes the 4-year clinical outcomes. METHODS AND RESULTS The ABSORB Cohort A trial enrolled 30 patients with a single de novo native coronary artery lesion. Clinical follow-up was available in 29 patients since one patient withdrew consent after the six month follow-up. At four years, the hierarchical ID-MACE of 3.4% remained… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
58 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 58 extracted citations

Similar Papers

Loading similar papers…